DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

How Can Pharma Find Success in the Evolving Immune Checkpoint Inhibitor Pipeline?

The immune checkpoint inhibitor clinical landscape is bustling with activity, with more than 1,000 trials for currently available products scheduled to complete between 2018 and 2020.

Despite the challenges associated with the class – such as recent high-profile combination failures – opportunities remain.

However, the rapid ongoing development of agents means the available ‘white space’ is closing, or at least changing, almost on a weekly basis.

Dr. Andrew Merron, Executive Director, DRG Oncology reviews competitor activities and how drug developers can take advantage of the best opportunities for success:

  • How are immune checkpoint inhibitors transforming the oncology space?
  • What is the current state of the market and how has indication strategy evolved?
  • Which brands and indications have the greatest uptake in the real world?
  • What is the competitive landscape for clinical development?
  • What are the combination strategies among current players?
  • What’s next for immune checkpoint inhibitors?
  • How can brands find success in the future immune checkpoint inhibitor market?

 

Please complete the form for answers to the above questions: